Bending The "Commercialization Curve" In Large Pharma

By Greg Skalicky, President & Chief Revenue Officer

It’s more important than ever to embrace change and new ways to bring therapies to patients, especially when considering commercialization and globalization in the life sciences and pharmaceutical industries.

Although many would agree that this adaptation is important, we haven’t seen much change in the last 30 years in the way larger companies are bringing drugs to market. Failure to adapt and embrace new ways of doing things can cause significant challenges for the industry, creating downstream impacts across healthcare, the largest of which is on patients.

This paper covers the following four critical areas:

• Agility to support the changing pipeline landscape
• Single-partner outsourcing model in commercialization
• Tapping into supplemental revenue streams: reignite established brands and increase in-licensing pipeline
• Gaining competitiveness in digital